Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Nov 14 - Nov 19
Ottaviani M, Alestas T, Flori E, Mastrofrancesco A, Zouboulis CC, Picardo M
MADE IN USA Manufactured in the USA in GMP-certified facilities using high-quality ingredients and rigorous quality standards
REDEFINE 1 (Garvey et al., NEJM 2025) is the only Phase 3 trial of an amylin + incretin co-administered combination, pairing cagrilintide 2.4 mg with semaglutide 2.4 mg
Rare Side Effects: 1
It is used in research settings to investigate cytoprotective signaling and tissue-repair mechanisms, including experimentally reported effects in preclinical models relevant to gastrointestinal mucosal integrity, angiogenic signaling, and inflammatory modulation
